These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

739 related items for PubMed ID: 14609359

  • 1. Octreotide long-acting release (LAR): a review of its use in the management of acromegaly.
    McKeage K, Cheer S, Wagstaff AJ.
    Drugs; 2003; 63(22):2473-99. PubMed ID: 14609359
    [Abstract] [Full Text] [Related]

  • 2. Octreotide long-acting release (LAR): a review of its use in the management of acromegaly.
    Yang LP, Keating GM.
    Drugs; 2010 Sep 10; 70(13):1745-69. PubMed ID: 20731479
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly.
    Amato G, Mazziotti G, Rotondi M, Iorio S, Doga M, Sorvillo F, Manganella G, Di Salle F, Giustina A, Carella C.
    Clin Endocrinol (Oxf); 2002 Jan 10; 56(1):65-71. PubMed ID: 11849248
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Octreotide long-acting release (LAR). A review of its pharmacological properties and therapeutic use in the management of acromegaly.
    Gillis JC, Noble S, Goa KL.
    Drugs; 1997 Apr 10; 53(4):681-99. PubMed ID: 9098666
    [Abstract] [Full Text] [Related]

  • 7. [Cost-effectiveness analysis of octreotide long acting release and lanreotide slow release for the treatment of postoperative patients with active acromegaly in China].
    Xuan JW, Zhang ZY, Wang YF, Mao ZG, Lu YJ, Wang RZ.
    Zhonghua Yi Xue Za Zhi; 2017 Mar 14; 97(10):765-769. PubMed ID: 28316158
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Efficacy of a slow-release formulation of lanreotide (Autogel) 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study.
    Ronchi CL, Boschetti M, Degli Uberti EC, Mariotti S, Grottoli S, Loli P, Lombardi G, Tamburrano G, Arvigo M, Angeletti G, Boscani PF, Beck-Peccoz P, Arosio M, Italian Multicenter Autogel Study Group in Acromegaly.
    Clin Endocrinol (Oxf); 2007 Oct 14; 67(4):512-9. PubMed ID: 17555511
    [Abstract] [Full Text] [Related]

  • 11. First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial.
    Colao A, Pivonello R, Rosato F, Tita P, De Menis E, Barreca A, Ferrara R, Mainini F, Arosio M, Lombardi G.
    Clin Endocrinol (Oxf); 2006 Mar 14; 64(3):342-51. PubMed ID: 16487447
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly.
    Colao A, Ferone D, Marzullo P, Cappabianca P, Cirillo S, Boerlin V, Lancranjan I, Lombardi G.
    J Clin Endocrinol Metab; 2001 Jun 14; 86(6):2779-86. PubMed ID: 11397887
    [Abstract] [Full Text] [Related]

  • 15. A comparison of lanreotide and octreotide LAR for treatment of acromegaly.
    Turner HE, Vadivale A, Keenan J, Wass JA.
    Clin Endocrinol (Oxf); 1999 Sep 14; 51(3):275-80. PubMed ID: 10469005
    [Abstract] [Full Text] [Related]

  • 16. The effect of a new slow-release, long-acting somatostatin analogue, lanreotide, in acromegaly.
    al-Maskari M, Gebbie J, Kendall-Taylor P.
    Clin Endocrinol (Oxf); 1996 Oct 14; 45(4):415-21. PubMed ID: 8959079
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.
    Jallad RS, Musolino NR, Salgado LR, Bronstein MD.
    Clin Endocrinol (Oxf); 2005 Aug 14; 63(2):168-75. PubMed ID: 16060910
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group.
    Giusti M, Gussoni G, Cuttica CM, Giordano G.
    J Clin Endocrinol Metab; 1996 Jun 14; 81(6):2089-97. PubMed ID: 8964833
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.